The treatment for cutaneous melanoma has entered a brand-new era of immunotherapy and targeted therapy. Immune checkpoint inhibitors and BRAF/MEK inhibitors have dramatically improved survival outcomes in both metastatic settings and adjuvant settings. Meanwhile, for acral and mucosal melanoma, the efficacy of current mainstream treatment remains unclear. Several studies have implied that a single approach might be inefficient due to lower tumor mutation burden and worse immune microenvironment of these two subtypes. It is still urging to fully understand the genomic alternation as well as its impact on anti-tumor immunity, to develop more precise treatment or multi-disciplinary approaches. Potential strategies include i) using new techniques such as single-cell RNA-seq or spatial transcriptome profiling to investigate the oncogenic specificity and intratumoral diversity of immune cells, ii) combining anti-PD1-based immunotherapy with other novel or conventional therapy to tackle the tumor microenvironment, iii) developing multi-targeted therapies to tumorigenesis-associated mutation other than BRAFV600 or overcome the secondary resistance.
This Research Topic aims to analyze the potential therapeutical factors attributing to the worse outcomes by summarizing status of treatment for acral and mucosal melanoma, to further investigate the biology of these two rare subtypes with translational studies involving new genomic sequencing and transcriptome profiling techniques, and develop potential clinical strategies to realize the precision medicine and multi-disciplinary approaches for future practice including combining anti-PD1 based immunotherapy with other treatments, or multi-targeted therapies aiming other rare mutation and solving secondary resistance. We welcome submissions covering but not limited to the following:
1) Clarification of current key unresolved issues in the treatment of acral and mucosal melanoma
2) Investigation on molecular biology of acral and mucosal melanoma, including the oncogenic specificity and tumor microenvironment based on novel techniques
3) Investigation on potential therapy strategies based on anti-PD1-based combination via in vivo or in vitro model, as well as the related impact on T-cell function or anti-tumor immunity
4) Development of in vivo or in vitro models for potential targeted therapies overcoming secondary resistance to BRAF/MEK inhibitors in melanoma.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The treatment for cutaneous melanoma has entered a brand-new era of immunotherapy and targeted therapy. Immune checkpoint inhibitors and BRAF/MEK inhibitors have dramatically improved survival outcomes in both metastatic settings and adjuvant settings. Meanwhile, for acral and mucosal melanoma, the efficacy of current mainstream treatment remains unclear. Several studies have implied that a single approach might be inefficient due to lower tumor mutation burden and worse immune microenvironment of these two subtypes. It is still urging to fully understand the genomic alternation as well as its impact on anti-tumor immunity, to develop more precise treatment or multi-disciplinary approaches. Potential strategies include i) using new techniques such as single-cell RNA-seq or spatial transcriptome profiling to investigate the oncogenic specificity and intratumoral diversity of immune cells, ii) combining anti-PD1-based immunotherapy with other novel or conventional therapy to tackle the tumor microenvironment, iii) developing multi-targeted therapies to tumorigenesis-associated mutation other than BRAFV600 or overcome the secondary resistance.
This Research Topic aims to analyze the potential therapeutical factors attributing to the worse outcomes by summarizing status of treatment for acral and mucosal melanoma, to further investigate the biology of these two rare subtypes with translational studies involving new genomic sequencing and transcriptome profiling techniques, and develop potential clinical strategies to realize the precision medicine and multi-disciplinary approaches for future practice including combining anti-PD1 based immunotherapy with other treatments, or multi-targeted therapies aiming other rare mutation and solving secondary resistance. We welcome submissions covering but not limited to the following:
1) Clarification of current key unresolved issues in the treatment of acral and mucosal melanoma
2) Investigation on molecular biology of acral and mucosal melanoma, including the oncogenic specificity and tumor microenvironment based on novel techniques
3) Investigation on potential therapy strategies based on anti-PD1-based combination via in vivo or in vitro model, as well as the related impact on T-cell function or anti-tumor immunity
4) Development of in vivo or in vitro models for potential targeted therapies overcoming secondary resistance to BRAF/MEK inhibitors in melanoma.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.